|  | FREE WEBINAR: Decoding the Vaginal Microbiome Don't miss the chance to hear Priyanka Jain, CEO & Co-Founder at Evvy discuss their mission to close the gender health gap by leveraging overlooked biomarkers and using metagenomic sequencing to better understand the vaginal microbiome. Register Now! |
|---|
- Alcon swoops on Aerie, striking $770M buyout to expand eye drug pipeline
- Moderna co-founder helps finance Belgian mRNA shop
- Foghorn downgraded to full clinical hold, with more patient deaths clouding AML, MDS trial
- Merck, seeking XI factor in race with Bayer, gets FDA fast-track tag for anticoagulant
- Windtree takes weight off branches, enters near $80M biobucks deal for acute pulmonary pipeline platform
- Not all cancer associated fibroblasts are created equal—some promote, some suppress drug resistance
- Alpha Cognition's delayed-release Alzheimer's drug hits goal, teeing up approval filing
- Compliance with Oct. 6 data blocking regulations will suffer without more clarity, stakeholders tell HHS
- Digital Diagnostics dials up $75M funding for diabetic retinopathy AI
- UPDATED: Teva won't reopen troubled California site, where 300-plus are losing their jobs
- Judge rules CMS unfairly overturned Georgia's Medicaid work requirements program
- GSK claps back at Teva in 'skinny' label case, arguing verdict doesn't threaten companies who act 'properly'
Featured Story By Nick Paul Taylor Alcon is buying in pipeline prospects to support its expansion into the eye drug market, striking a $770 million takeover of Aerie Pharmaceuticals to add two approved therapies and a clutch of investigational treatments for retinal and ocular surface diseases. read more |
| |
|---|
|
Top Stories By Max Bayer Moderna co-founder Kenneth Chien is staying close to budding mRNA-based biotechs, investing in eTheRNA's latest 39 million euro series B. As a result, he'll join the company's board, alongside fellow investor and VC founder Marijn Dekkers. read more By Max Bayer Three months after the FDA sent a warning to Foghorn via a partial clinical hold on its phase 1 trial, regulators have become even more dismayed, downgrading the company's study to a full hold in light of additional patient deaths. read more By Nick Paul Taylor The FDA has delivered a boost to Merck’s mission to provide a standard of care anticoagulation therapy for end-stage renal disease (ESRD) patients by slapping a fast-track tag on midphase asset MK-2060. read more By Gabrielle Masson Windtree Therapeutics is taking weight off its branches, entering a global licensing deal with Lee’s Pharmaceutical and Zhaoke Pharmaceutical that offers more than $78.9 million in potential biobucks for several acute pulmonary pipeline treatments. read more By Zoey Becker Cancer-associated fibroblasts are commonly believed to induce drug resistance. But when researchers at Moffitt Cancer Center took a closer look at the fibroblasts, they discovered that while some induce drug resistance, some induce drug sensitivity. read more By Nick Paul Taylor Alpha Cognition has taken another step toward a filing for approval of its delayed-release treatment for Alzheimer’s disease, publishing top-line results from a study that compared the prospect to an incumbent product. read more By Dave Muoio Scenario-specific FAQs, clearer definitions and technical assistance will go a long way toward helping providers meet new info blocking regulations slated for Oct. 6, stakeholders including Ascension, Epic, Mayo Clinic, AMIA and the HIMSS told HHS. read more By Andrea Park Not long after forging a partnership with Baxter earlier this year, Digital Diagnostics has roped in $75 million in series B funding to build out the reach of IDx-DR and its other AI-powered diagnostic tools, the company announced Tuesday. read more By Fraiser Kansteiner Teva Parenteral Medicines is letting go of 305 staffers at its site at 19 Hughes, Irvine, California, according to a local Worker Adjustment and Retraining Notification Act notice. In a statement, the company said it's moving to close the troubled site. read more By Robert King A federal judge sided with Georgia that CMS unfairly struck down the state's Medicaid work requirements program, saying that the decision was arbitrary. read more By Kevin Dunleavy GSK has urged the U.S. Supreme Court to reject Teva's petition to reopen its patent infringement case over blood pressure drug Coreg. Teva argues that the verdict could have dire consequences for the generics industry and its ability to use "skinny" labels. read more Resources Sponsored by: Ferma.AI, a Product of ZoomRx Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Bio-Techne Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. |
|
